Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Non-Current Assets (2017 - 2025)

Arcus Biosciences (RCUS) has 8 years of Other Non-Current Assets data on record, last reported at $63.0 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed N/A year-over-year to $63.0 million; the TTM value through Dec 2025 reached $63.0 million, changed N/A, while the annual FY2025 figure was $63.0 million, N/A changed from the prior year.
  • Other Non-Current Assets reached $63.0 million in Q4 2025 per RCUS's latest filing, down from $65.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $116.0 million in Q4 2021 and bottomed at $2.0 million in Q1 2021.
  • Average Other Non-Current Assets over 4 years is $53.1 million, with a median of $64.0 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 57042.86% in 2021, then tumbled 94.74% in 2023.
  • A 4-year view of Other Non-Current Assets shows it stood at $116.0 million in 2021, then fell by 1.72% to $114.0 million in 2022, then crashed by 94.74% to $6.0 million in 2023, then surged by 950.0% to $63.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $63.0 million in Q4 2025, $65.0 million in Q3 2025, and $69.0 million in Q2 2025.